• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    VanEck Pharmaceutical ETF (NQ:PPH)

    102.08 -0.12 (-0.12%)
    Streaming Delayed Price Updated: 10:45 AM EDT, Mar 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about VanEck Pharmaceutical ETF

    < Previous 1 2 3 Next >
    News headline image
    FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗
    FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television. 
    Via Stocktwits
    Topics Government
    News headline image
    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
    Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗
    A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
    Via Benzinga
    News headline image
    FDA Aims To Reduce Drug Application Review Time With New Voucher Program ↗
    The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final... 
    Via Stocktwits
    News headline image
    Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗
    The Trump administration unveiled the first details Tuesday on how it plans to lower drug prices "drastically" in the U.S. 
    Via Investor's Business Daily
    Topics ETFs Government
    News headline image
    Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗
    Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket. 
    Via Benzinga
    Topics Government
    News headline image
    Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
    Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
    Via Benzinga
    Topics ETFs Government
    News headline image
    Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗
    Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
    Via Stocktwits
    Topics Government Intellectual Property Lawsuit
    News headline image
    Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
    Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
    Via Benzinga
    Topics Government World Trade
    News headline image
    Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises ↗
    The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
    Via Stocktwits
    Topics Earnings
    News headline image
    VanEck Announces Year-End Distributions for VanEck Equity ETFs
    From VanEck
    Via Business Wire
    News headline image
    Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report ↗
    Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
    Via Benzinga
    News headline image
    Just Say No to Drugs: 3 Pharma Stocks to Avoid ↗
    Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
    Via InvestorPlace
    News headline image
    A Look At Pharma ETFs Post Q1 Earnings ↗
    Pharma ETFs have delivered mixed performances over the past month. 
    Via Talk Markets
    Topics ETFs
    News headline image
    ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook ↗
    Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
    Via Talk Markets
    Topics ETFs
    News headline image
    3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗
    Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
    Via InvestorPlace
    Topics ETFs
    News headline image
    Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage ↗
    Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. 
    Via Benzinga
    News headline image
    The Top 3 ETFs to Buy in March 2024 ↗
    Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. 
    Via InvestorPlace
    Topics ETFs
    News headline image
    11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
    A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
    Via Benzinga
    News headline image
    A Look At Pharma ETFs After Q4 Earnings ↗
    The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
    Via Talk Markets
    Topics ETFs
    News headline image
    5 ETF Zones Scaling New Highs At The Start Of 2024 ↗
    The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs. 
    Via Talk Markets
    Topics ETFs
    News headline image
    Government-granted Patent Monopolies Are Not The Free Market ↗
    Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... 
    Via Talk Markets
    Topics Intellectual Property
    News headline image
    Preparing For The Next Short-Term Rally Higher ↗
    The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next... 
    Via Talk Markets
    News headline image
    Pharma ETFs in Focus Post Q2 Earnings ↗
    Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
    Via Talk Markets
    Topics ETFs
    News headline image
    The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023 ↗
    Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
    Via InvestorPlace
    News headline image
    Pharma ETFs Gain Post Q1 Earnings ↗
    Pharma ETFs have been in the green over the past month. 
    Via Talk Markets
    News headline image
    A Look At Pharma ETFs Post Q4 Earnings ↗
    Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
    Via Talk Markets
    News headline image
    5 Sector ETFs That Beat The Market In December ↗
    While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail. 
    Via Talk Markets
    News headline image
    Pharma ETFs In Focus Post Q3 Earnings ↗
    Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
    Via Talk Markets
    News headline image
    Wave of Solid Q3 Earnings Push Pharma ETFs Higher ↗
    The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
    Via Talk Markets
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.